Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000413289 | SCV000491924 | uncertain significance | not specified | 2016-11-29 | criteria provided, single submitter | clinical testing | The S4513N variant in the SACS gene has been reported in the heterozygous state along with two other variants in the SACS gene, phase unknown, in one individual with early-onset ataxia and spasticity (Synofzik et al., 2013). The S4513N variant was not observed with any significant frequency in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The S4513N variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position where amino acids with similar properties to Serine are tolerated across species. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Therefore, we interpret S4513N as a variant of uncertain significance. |
Labcorp Genetics |
RCV002523949 | SCV003454150 | likely benign | Spastic paraplegia | 2023-12-13 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001274915 | SCV001459468 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2020-09-16 | no assertion criteria provided | clinical testing |